After A Gargantuan Year For Pharma M&A, More To Come In 2015
The year 2014 was the biggest for pharma M&A in recent history, though it may be remembered equally for sagas and upsets that never materialized into finalized deals. Actavis, in the end, was the most aggressive acquirer, buying Forest and Allergan for a total of $89.3 billion in the two most expensive deals of the year.
You may also be interested in...
Big Pharma Is Back In The M&A Driver’s Seat For 2017
Big pharma is poised to dominate deal-making this year while the firepower of specialty pharma to do deals has waned. 2017 could be a record year for M&A, EY predicts in its annual M&A Outlook and Fire Power Report.
In Buzz Of 2015 Pharma Dealmaking, Immuno-Oncology Is Queen Bee
Big pharma keeps marching into immuno-oncology, and partnering in the field has been one of the biggest deal drivers of 2015. It’s not yet a big factor in M&A, which this year has been driven by payer pressure and generics consolidation.
Pharma M&A Booming In First Eight Months Of The Year
The year 2015 could give 2014 a run for the money in terms of biopharma M&A deal value. From January through August, 18 deals were signed with an upfront value of more than $1bn, representing a total upfront value of $133bn.